Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

@article{Dotto2001IntravenousAI,
  title={Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.},
  author={Paolo Del Dotto and Nicola Pavese and Gianna Gambaccini and Silvia Bernardini and Leo Verhagen Metman and Thomas N. Chase and Ubaldo Bonuccelli},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={2001},
  volume={16 3},
  pages={515-20}
}
Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely… CONTINUE READING